Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced basal cell carcinoma.

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable ...

Senhwa Biosciences announces positive data from phase 1/expansion trial of Silmitasertib for basal cell carcinoma treatment: Taipei, Taiwan Thursday, April 3, 2025, 15:00 Hrs [IST ...

Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...

Optimal Treatment Response: Three patients achieved partial response ... or in combination with the second-line immunotherapy Libtayo. The company aims to explore further indications and potential ...

Optimal Treatment Response: Three patients achieved partial response (PR), while ten ... potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company aims to ...

EMPOWER-Lung-3 enrolled subjects with both squamous and non-squamous tumours and all PD-L1 expression levels, so Libtayo's efficacy comes against a more heterogenous patient population.

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The vast ...